Spots Global Cancer Trial Database for To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
Official Title: An Extension Study to Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors.
Study ID: NCT01193140
Conditions
Study Description
Brief Summary: To evaluate the safety and tolerability of the veliparib/TMZ combination in subjects with solid tumors.
Detailed Description: An extension study to evaluate the safety of veliparib in combination with temozolomide in subjects with solid tumors
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site Reference ID/Investigator# 43022, Encinitas, California, United States
Site Reference ID/Investigator# 42662, Santa Monica, California, United States
Contact Details
Name: Bhardwaj Dessai, MD
Affiliation: Abbott
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
